The FDA approved a new monthly paliperidone palmitate (Erzofri) extended-release injectable suspension for treating schizophrenia in adults, Luye Pharma announced. An atypical antipsychotic, ...
TITUSVILLE, N.J., May 19, 2015 / PR Newswire / — There's a new treatment option for schizophrenia – INVEGA TRINZA™ (three-month paliperidone palmitate), the first and only schizophrenia medication to ...
Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study published ...
(RTTNews) - Janssen Pharmaceutical, Inc., wholly-owned by Johnson & Johnson (JNJ), announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback